Skip to main content

Table 1 Clinical characteristics of study population

From: Intracellular lactate signaling cascade in atrial remodeling of mitral valvular patients with atrial fibrillation

Parameters SR PaAF PeAF
Sex, M/F (n) 15/15 15/15 15/15
Age (years) 48.4±11.2 49.1.±10.1 48.7±10.8
Body mass index (kg/m 2 ) 23.2±2.8 22.9±2.4 22.2±3.1
Heart rate (beats/min) 74±9 77±11 78±15
Mean artery pressure (mm Hg) 84.6±7.2 86.6±9.4 83.2±10.2
C-reactive protein (mg/L) 2.86±1.02 4.32±0.94* 5.04±1.21* , **
Duration of valvular disease (years) 4.9±4.8 6.9±5.7 12.5±7.2* , **
NYHA class I/II/III/IV (n) 4/9/14/3 3/7/15/5 2/4/17/7
Echocardiographic parameters    
LVDd (mm) 48.6±7.4 50.4±6.8 49.2±8.1
LVDs (mm) 31.8±4.7 32.3±5.2 31.1±4.9
EF (%) 63.6±3.9 62.8±4.4 63.4±4.1
LAD (mm) 41.7±6.4 52.4±8.2* 59.9±9.4* , **
RAD (mm) 37.7±4.1 42.5±4.6* 46.3±5.7* , **
PASP (mm Hg) 34.2±7.7 44.1±11.3* 51.2±14.9* , **
Left atrial thrombus (n) 0 3 8* , **
Preoperative length of stay (days) 9.6±4.2 12.2±5.6* 15.8±6.8* , **
Cause of mitral valve disease (n)    
Rheumatic/degenerative 22/8 24/6 28/2* , **
Preoperative drug (n)    
Digitalis 30 30 30
Calcium-channel blocker 7 5 8
Beta-blocker 3 4 6
ACE-I 5 7 10
  1. Values are presented as mean±SD or number of patients.
  2. ACE-I angiotensin-converting enzyme inhibitor, EF ejection fraction, LAD left atrial diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, NYHA New York Heart Association, PASP pulmonary artery systolic pressure, RAD right atrial diameter.
  3. * p<0.05, reference group is the SR group.
  4. ** p<0.05, reference group is the PaAF group.